A specialty
vaccine company
Valneva at a glance
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
2024 Highlights
Valneva achieved several key milestones in 2024, including the Canadian and European approvals of Valneva’s single-shot chikungunya vaccine.
Our vaccine pipeline
At Valneva, we take a specialized approach to vaccine development, focusing on disease targets that lack a preventative or therapeutic solution.
Our strategy
Valneva aims to be a globally recognized vaccine company by innovating today and preserving tomorrow. Advancing vaccines for better lives.
Our Global Operations
To develop, manufacture, and commercialize vaccines globally, Valneva maintains sites and affiliates in six countries.
Our Commercial Business
Valneva commercializes its own vaccines against chikungunya, Japanese encephalitis and cholera, as well as third party-products, in key markets.